TY - JOUR
T1 - A novel deleterious ETFA promoter variant causative of multiple acyl-CoA dehydrogenase deficiency
AU - Prasun, Pankaj
AU - Evans, Anthony
AU - Cork, Emalyn
AU - Houten, Sander M.
AU - Webb, Bryn D.
N1 - Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2023/4
Y1 - 2023/4
N2 - Multiple acyl-CoA dehydrogenase deficiency (MADD) is an autosomal recessive disorder of fatty acid, amino acid, and choline metabolism. We describe a patient identified through newborn screening in which the diagnosis of MADD was confirmed based on metabolic profiling, but clinical molecular sequencing of ETFA, ETFB, and ETFDH was normal. In order to identify the genetic etiology of MADD, we performed whole genome sequencing and identified a novel homozygous promoter variant in ETFA (c.-85G > A). Subsequent studies showed decreased ETFA protein expression in lymphoblasts. A promoter luciferase assay confirmed decreased activity of the mutant promoter. In both assays, the variant displayed considerable residual activity, therefore we speculate that our patient may have a late onset form of MADD (Type III). Our findings may be helpful in establishing a molecular diagnosis in other MADD patients with a characteristic biochemical profile but apparently normal molecular studies.
AB - Multiple acyl-CoA dehydrogenase deficiency (MADD) is an autosomal recessive disorder of fatty acid, amino acid, and choline metabolism. We describe a patient identified through newborn screening in which the diagnosis of MADD was confirmed based on metabolic profiling, but clinical molecular sequencing of ETFA, ETFB, and ETFDH was normal. In order to identify the genetic etiology of MADD, we performed whole genome sequencing and identified a novel homozygous promoter variant in ETFA (c.-85G > A). Subsequent studies showed decreased ETFA protein expression in lymphoblasts. A promoter luciferase assay confirmed decreased activity of the mutant promoter. In both assays, the variant displayed considerable residual activity, therefore we speculate that our patient may have a late onset form of MADD (Type III). Our findings may be helpful in establishing a molecular diagnosis in other MADD patients with a characteristic biochemical profile but apparently normal molecular studies.
KW - ETFA
KW - MADD
KW - electron transfer flavoprotein
KW - glutaric acidemia II
KW - glutaric aciduria II
UR - http://www.scopus.com/inward/record.url?scp=85145305822&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.63104
DO - 10.1002/ajmg.a.63104
M3 - Article
C2 - 36579410
AN - SCOPUS:85145305822
SN - 1552-4825
VL - 191
SP - 1089
EP - 1093
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 4
ER -